Associated Papers
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
Herencia-Ropero A et al.
Genome Medicine, 2024
39187844 (PubMed )
Supplement: 13073_2024_1370_MOESM3_ESM.xlsx › SNV
Analysis of clinical characteristics and genetic testing in patients with acute fatty liver of pregnancy: a retrospective study.
Shi Y et al.
Bmc Pregnancy and Childbirth, 2021
34496798 (PubMed )
Supplement: 12884_2021_4095_MOESM3_ESM.xlsx › PASS_annova
Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential.
Yamato A et al.
Cancer Science, 2015
26094954 (PubMed )
Supplement: cas0106-1137-sd10.xlsx › Sheet1
Select a paper to view details